There is No Better Way to Cure a Broken Heart® news
| 15/04/08 | Article on PICSO® documents long term positive outcomes. The recent scientific article published by Prof. Mohl et al. in the Japanese Circulation Society Journal [Circ J 2008; 72:526-522] documents the long term positive outcomes in acute coronary syndrome patients (ACS) that have undergone revascularization by thrombolytics and received PICSO. The study randomized 133 ACS patients admitted for reperfusion (reperfusion alone vs. reperfusion+PICSO®). PICSO® was provided with fixed timed intervals of 5 seconds deflation and 10 seconds inflation. In the PICSO® group 54 patients received PICSO® of which 38 patients had successful reperfusion and 17 patients had their culprit lesion in the proximal left anterior descending coronary artery (LAD). These 17 PICSO® patients were compared with 17 patients with a proximal LAD stenosis and only undergoing reperfusion. In the PICSO® group the patients received 59±30 minutes of PICSO® and successful reperfusion was achieved within 28±12 minutes. The non- PICSO® group achieved reperfusion in 41±18 minutes which is significantly longer (p<0.05) than the PICSOTM group. At 60 months follow-up a significant difference (p<0.0001) between the two groups was demonstrated with regard to major adverse cardiovascular events (MACE). In addition to the reduced MACE, the PICSO® group also showed a lower restenosis value at 30 days (p=0.0126). After 48 months 100% of the patients in the PICSO® group but only 55.6% in the control group were free from re-myocardial infarction. The PICSO® group also showed longer cardiac event free survival (p<0.0001). Furthermore the relative risk for cardiac events was 8.4 times higher in the control group than in the PICSO® group. This study is based on patients completed in the early age of coronary reperfusion strategies. During the study a simple technology for occlusion of the coronary sinus was used. However, the results are very encouraging for the technical and clinical developments Miracor will initiate. The main objectives of the company are to develop a new PICSO® platform and to initiate new clinical trials to document the benefit of PICSO® using state-of-the-art reperfusion strategies. |
news
receive news alerts
Last updated: 29/06/10Miracor Medical Systems GmbH, Mariannengasse 14/14, A-1090 Vienna Austria · t +43 (0) 1 - 236 657 612 · f +43 (0) 1 - 236 657 622 · picso[at]miracormedical.com
